Clinical Trial ResultsAlpha Tau Medical reported positive interim results for the first eight patients receiving a combination of Alpha DaRT and Keytruda for the treatment of recurrent unresectable or metastatic head and neck squamous cell carcinoma, with a systemic objective response rate of 75%.
Manufacturing ProgressThe Hudson, NH facility is slated to complete its first phase of construction and come online for production of Alpha DaRT, indicating progress in manufacturing capabilities.
Regulatory DevelopmentsThe company received an IDE from the FDA to conduct a U.S. pilot study of Alpha DaRT in patients with recurrent glioblastoma multiforme (GBM).
Strategic InvestmentA $36.9M strategic investment from Oramed validates Alpha Tau’s novel technology and its potential in oncology therapeutics.